50-year-old Linzongbai two temples some grizzled, he done in the pharmaceutical industry for 30 years. 10 years of time spent on the mainland. In 30 years of history, he had worked as a scientist at DuPont, GlaxoSmithKline and other companies based in the United States, research and development base, as a businessman have busied themselves at the United States, Europe and Hong Kong and Taiwan and the Chinese mainland belong to the medium-sized pharmaceutical market pushed open the door to China acted as a go-between. Flying in Europe and the United States and between the two sides three days seemed to be very relaxed because Linzongbai a certain economic foundation. In the United States, he has been called a Nu Bio biotechnology companies, and others and set a pharmaceutical company; in a suburb of Beijing, he had a small chemical plant and a pharmaceutical consulting firm. "I earned a day of 1500 dollars. "Linzongbai this appraisal of his own worth. As an American of Chinese pharmaceutical specialists, The Taiwan people in the industry are seen as a drug market at home and abroad have a thorough understanding of the business, only rely on the wealth of experience to Peace among the animals. But now, the Jinling Union has experts from Changzhi City of Shanxi Province Aung Health Medical Group Ltd., and the company as a consultant in China to promote his invention of a drunken --RU18 patented products. With a remote from the mainland enterprises, promotion of a growing epidemic in the United States of products, Linzongbai is by virtue of his experience and unique perspective in the pharmaceutical and health products markets in search of business opportunities. Xingjiubaogan market potential is so great that even a few years ago it was precisely because of Haiwang Group Haiwang Jinzun dominate, and has kept more than 100 million yuan in sales. Chinese medicine, health care products market has its own rules, some foreign companies may enter hastily thrown riders down their stumbled horses, Linzongbai than others and understand how to escape the rocks and digging of gold, This stems from the Chinese mainland in more than 10 years of business experience. Linzongbai 1974 from a Taiwan university graduate professional pharmacy, three years after the United States obtained a doctorate toxicology. 上世纪80年代的美国制药业对毒理学专业人才正如饥似渴，凭着一张毒理学博士文凭，Linzongbai 10 years for the three companies, including DuPont, Wellcome (GlaxoSmithKline's predecessor) so handsomely paid to the enterprises. He said : "Our performance in the pharmaceutical enterprises can only be the best annual 10-15% rise, and I quit. each 40%-45% wages can rise. "Taiwan people, Chinese mainland market charm is unstoppable. The data show that in 2004 business in the Chinese mainland or in Taiwan nearly one million, together with their immediate families, the total population of up to 300-400 million, accounting for 15-20% of the total population. Chinese mainland market on the charm in the late 1970s had already let a few people in Taiwan feel, Linzongbai is one of them. At that time he graduated not long, with a visit mainland China delegation to visit the mainland. He inspected the observed walking the shops, canteens commune or communes, and the widespread use of the canteen food stamp surprised. “那时我对大陆的一切都强烈地好奇，I think increasingly the future must join this broad market. , "he recalls. In 1991, the company Linzongbai several proposals to develop the Chinese mainland market, but we had not been adopted. He eventually had to leave the company alone to dream chaser. Three years later, Linzongbai become France Luonapulangke (China), pharmaceutical companies (Sainuofei -- An 10,000-te) was the Director of Business , which he began to explore the conditions of the pharmaceutical market in China. The results, when 10 years after he left, this time he first arrived in China sold only two and a half drug company's business has grown 20 times. That 10 years of a Linzongbai found in the Chinese medicine trade promotion so difficult, As for the relations are very opaque, up processing complex. This prompted him to the United States set up a two companies, China in building a pharmaceutical intermediates production of small plants and a specialized help to people doing drugs approved the consulting firm. To a certain extent, yes Linzongbai medicine in China to tap the market recognition of his gold. China has a population of 1.3 billion, in the last 20 years has been maintained above 8% economic growth rate. According famous consulting firm predicts that by 2010, China will become the world's third largest pharmaceutical market. after the United States and Japan. However, China's vast size and large urban agglomerations pioneering pharmaceutical market so that the cost is too high. For the research and development of new drugs, is that some prescription drugs, if we want to promote to the mainland market, on the need for a city to city to open, will each house to a hospital research centers, obviously spent a lot of money. So relatively speaking, the promotion of non-prescription drugs (OTC) to be easier, in the national media advertising. In domestic reputation loud Most pharmaceutical companies through this route, such as the 8 healthy volunteers after their taking, the United States saw the Astemizole, miconazole, Hypertension. However, this also requires large investments. Linzongbai said that the 50 million a year simply will not work. Foreign pharmaceutical companies, the Chinese market still has a number of other traps, such as the protection of intellectual property issues. After a decade of do business according to their intuition, Linzongbai domestic intellectual property right protection is personal experience. Rhone-Poulenc of patented drugs Spiramycin, domestic counterparts imitation later renamed as Acetylspiramycin. but also occupied the majority of the market. Although the situation has improved, For example, to imitate the latest drugs by the state granted the two types of new drugs have rarely appeared, But small and medium-sized pharmaceutical companies to enter into China is still a dilemma. China, implies approval for the new product investment and time. In China, drug approval is often possible to spend a year or 23 hours, and getting approval, market also need to build costly networks. Help small and medium-sized overseas listed China Linzongbai now is the main line of business. With the Chinese market in the years accumulated experience and relationships Linzongbai not only for small and medium-sized overseas enterprises and approval of pharmaceutical drugs, They also introduce the domestic pharmaceutical sales channels. Help pharmaceutical products approved abroad as CRO (Contract Research O rganization), but the domestic market in the profit is not insurance, The reason is that China's pharmaceutical sector Drug Administration approved the system is in continuous advanced system closer, Evolution among ever. Linzongbai met on such a matter. Once, he spent several months on experimental data collation, summed up well the thick material, State approval coincides with the audit requirements change, it makes him very hard to go down the drain. "Approval of a drug, if successful might only need five million dollars and six months, but if not successful, may be a delay of two to three years, spent 200,000 U.S. dollars not work. , "he said. After comparing his decision to cooperate with the pharmaceutical companies and free enterprise filings, at its own risk, But the conditions to full Acting products in China five years and sold. This model is a direct test of the 30 drugs Linzongbai marketing career of two things -- the vision and experience However, the small number of overseas pharmaceutical companies run is a good idea. Germany, for example, Juma is a factory with an annual sales volume of 500 million euros and medium-sized enterprises, in accordance with the strength, it does not have the capacity alone to enter the Chinese market. Linzongbai 1999, this enterprise as a consultant to help it tackle the Chinese market problems encountered. Last year, Juma's sales in China have close to 600 million euros, which is a remarkable achievement. Linzongbai customers also include German history Dade and several other manufacturers in Europe and Taiwan pharmaceutical companies. His efforts to promote foreign manufacturer's investment in China. in the market in mainland China stand firm eventually enterprises will invest and build factories to stabilize sales and avoid risks -- in the country, Drug imports annually after two tests, such as failure license will be revoked, and set up factories in mainland China, just not the case.